European drug pricing: Jam tomorrow, log-jam today
This article was originally published in Scrip
Executive Summary
The European Parliament has agreed on potential changes to outdated European legislation that if approved could eventually bring generic medicines to the market more quickly. However, the end is by no means in sight as EU member states are still to thrash out their position on the revision, and ministers in the national governments of the European Union are understood to have a number of concerns about its contents.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.